Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Novel Method of Treating Cancer Using Ixolaris

Posted Jun 15 2010 5:00pm

Description of Invention:
Aggressive tumors spread between tissues in a process known as metastasis. Tumor metastasis, particularly with regard to brain cancer (gliomas), has been linked to the aberrant expression of membrane-bound tissue factor (TF). TF normally functions as a blood coagulation factor and can lead to the production of pro-angiogenesis factors such as vascular endothelial growth factor (VEGF). By doing this in the vicinity of tumors, TF may enhance both tumor growth and the ability of tumors to metastasize.

Ixolaris is a protein that prevents the initiation of blood coagulation, specifically by inhibiting TF. NIH inventors have explored the possibility that Ixolaris could be effective as an anti-cancer therapy. As an inhibitor of TF, Ixolaris could potentially inhibit the function of TF, thereby reducing the ability of a tumor to develop and to metastasize. Recent data show that Ixolaris has the ability to prevent tumor growth in vivo using mouse xenograft models. Importantly, the inhibition in vivo occurred without noticeable bleeding. Since Ixolaris is not immunogenic, it might be an excellent candidate as an anti-cancer therapeutic.

Applications:
Treatment and prevention of tumor growth and metastasis by inhibiting TF and blood vessel formation

Advantages:
Provides a novel mechanism for preventing tumor metastasis

Development Status:
Preclinical stage of development

Inventors:
Ivo Francischetti (NIAID)
Robson Q Monteiro (Federal University of Rio de Janeiro)
Jose M Ribeiro (NIAID)


Patent Status:
HHS, Reference No. E-148-2009/1
US, Application No. 61/225,961 filed 16 Jul 2009


Relevant Publication:
  1. US Patent 7,078,508 entitled "Ixodes Scapularis Tissue Factor Pathway Inhibitor"
  2. IM Francischetti et al. Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex. Blood 2002 May 15;99(10):3602-3612. [ PubMed: 11986214 ]
  3. RA Nazareth et al. Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade. Thromb Haemost. 2006 Jul;96(1):7-13. [ PubMed: 16807644 ]


Licensing Status:
Available for licensing

Collaborative Research Opportunity:
The NIAID, OTD, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Ixolaris for cancer treatment. Please contact Dana Hsu at 301-496-2644 for more information.


Portfolios:
Cancer
Cancer - Therapeutics
In-vivo Data



For Additional Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 1951

Updated: 06/2010

Post a comment
Write a comment:

Related Searches